Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V(30) and transforming growth factor beta.

[1]  P. Maguire,et al.  73.6 Gy and beyond: hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Anscher,et al.  The physical parameters and molecular events associated with radiation-induced lung toxicity. , 2000, Seminars in radiation oncology.

[3]  J A Purdy,et al.  Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC) , 1999, International journal of radiation oncology, biology, physics.

[4]  M T Munley,et al.  Incorporation of functional status into dose-volume analysis. , 1999, Medical physics.

[5]  R. Komaki,et al.  Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. , 1999, The New England journal of medicine.

[6]  R. Henriksson,et al.  Effects of ongoing smoking on the development of radiation-induced pneumonitis in breast cancer and oesophagus cancer patients. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  R K Ten Haken,et al.  Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. , 1998, International journal of radiation oncology, biology, physics.

[8]  R. Jaszczak,et al.  Regional dose response to pulmonary irradiation using a manual method. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  D. Sugarbaker,et al.  Clinical radiation pneumonitis and radiographic changes after thoracic radiation therapy for lung carcinoma , 1998, Cancer.

[10]  M T Munley,et al.  Physical and biological predictors of changes in whole-lung function following thoracic irradiation. , 1997, International journal of radiation oncology, biology, physics.

[11]  X. Fu,et al.  Hyperfractionated accelerated radiation therapy for non-small cell lung cancer: clinical phase I/II trial. , 1997, International journal of radiation oncology, biology, physics.

[12]  M. Graham.  Predicting radiation response. , 1997, International journal of radiation oncology, biology, physics.

[13]  Ž. Vujašković,et al.  315 Plasma TGF-B levels during radiotherapy with or without carboplatin predicts pneumonitis in stage III non-small cell lung cancer (NSCLC) , 1997 .

[14]  H. Ueoka,et al.  Risk factors for development of radiation pneumonitis following radiation therapy with or without chemotherapy for lung cancer. , 1997, International journal of radiation oncology, biology, physics.

[15]  M. Anscher,et al.  Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis. , 1997, International journal of radiation oncology, biology, physics.

[16]  T. Dix,et al.  Redox-mediated activation of latent transforming growth factor-beta 1. , 1996, Molecular endocrinology.

[17]  J. Purdy,et al.  Evaluation of an objective plan-evaluation model in the three dimensional treatment of nonsmall cell lung cancer. , 1996, International journal of radiation oncology, biology, physics.

[18]  D. Gandara,et al.  Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  P Schraube,et al.  Estimation of pneumonitis risk in three-dimensional treatment planning using dose-volume histogram analysis. , 1995, International journal of radiation oncology, biology, physics.

[20]  M. Anscher,et al.  Elevated Plasma Transforming Growth Factor-β1 Levels in Breast Cancer Patients Decrease After Surgical Removal of the Tumor , 1995, Annals of surgery.

[21]  R W de Boer,et al.  Estimation of overall pulmonary function after irradiation using dose-effect relations for local functional injury. , 1995, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[22]  A. Melman,et al.  Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer , 1995, Nature Medicine.

[23]  N. Mendenhall,et al.  Is radiation treatment volume a predictor for acute or late effect on pulmonary function? A prospective study of patients treated with breast‐conserving surgery and postoperative irradiation , 1994, Cancer.

[24]  Y. Matsuzawa,et al.  Plasma transforming growth factor‐β1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases , 1994, Cancer.

[25]  R K Ten Haken,et al.  Dose-volume histogram and 3-D treatment planning evaluation of patients with pneumonitis. , 1994, International journal of radiation oncology, biology, physics.

[26]  K. Shin,et al.  The influence of field size and other treatment factors on pulmonary toxicity following hyperfractionated irradiation for inoperable non-small cell lung cancer (NSCLC)-analysis of a radiation therapy oncology group (RTOG) protocol , 1993 .

[27]  T G Turkington,et al.  The utility of SPECT lung perfusion scans in minimizing and assessing the physiologic consequences of thoracic irradiation. , 1993, International journal of radiation oncology, biology, physics.

[28]  M. Anscher,et al.  Transforming Growth Factor β as a Predictor of Liver and Lung Fibrosis after Autologous Bone Marrow Transplantation for Advanced Breast Cancer , 1993 .

[29]  Y. Matsuzawa,et al.  Elevated Levels of Plasma Transforming Growth Factor‐β in Patients with Hepatocellular Carcinoma , 1992, Japanese journal of cancer research : Gann.

[30]  E. Ruoslahti,et al.  Transforming growth factor-beta in disease: the dark side of tissue repair. , 1992, The Journal of clinical investigation.

[31]  K. Miyazono,et al.  TGF-β1 binding protein: A component of the large latent complex of TGF-β1 with multiple repeat sequences , 1990, Cell.

[32]  J. Lazo,et al.  Early increases in pulmonary mRNA encoding procollagens and transforming growth factor-beta in mice sensitive to cyclophosphamide-induced pulmonary fibrosis. , 1989, The Journal of pharmacology and experimental therapeutics.

[33]  J. Lazo,et al.  Alterations in pulmonary mRNA encoding procollagens, fibronectin and transforming growth factor-beta precede bleomycin-induced pulmonary fibrosis in mice. , 1988, The Journal of pharmacology and experimental therapeutics.

[34]  K. Watanabe,et al.  Age factor relevant to the development of radiation pneumonitis in radiotherapy of lung cancer. , 1988, International journal of radiation oncology, biology, physics.

[35]  R K Craig,et al.  Methods in molecular medicine. , 1987, British medical journal.

[36]  C. Perez,et al.  Principles and Practice of Radiation Oncology , 1987 .

[37]  W. Birchmeier,et al.  Transforming growth factor-beta inhibits endothelial cell proliferation. , 1986, Biochemical and biophysical research communications.

[38]  S. Dische,et al.  Primary tumor control after radiotherapy for carcinoma of the bronchus. , 1984, International journal of radiation oncology, biology, physics.

[39]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[40]  R. Clough,et al.  Plasma transforming growth factor β1 as a predictor of radiation pneumonitis , 1997 .

[41]  K Hirata,et al.  Risk factors of pneumonitis following chemoradiotherapy for lung cancer. , 1998, European journal of cancer.

[42]  L. Marks,et al.  High-dose, hyperfractionated, accelerated radiotherapy using a concurrent boost for the treatment of nonsmall cell lung cancer: unusual toxicity and promising early results. , 1996, International journal of radiation oncology, biology, physics.

[43]  S. Breit,et al.  Radiation and the lung: a reevaluation of the mechanisms mediating pulmonary injury. , 1995, International journal of radiation oncology, biology, physics.

[44]  M. Anscher,et al.  Normal tissue injury after cancer therapy is a local response exacerbated by an endocrine effect of TGFβ , 1995 .

[45]  M. Anscher,et al.  Changes in plasma TGFβ levels during pulmonary radiotherapy as a predictor of the risk of developing radiation pneumonitis , 1993 .

[46]  M. Saunders,et al.  The long-term outcome after radical radiotherapy for advanced localized non-small cell carcinoma of the lung. , 1993, Clinical oncology (Royal College of Radiologists (Great Britain)).

[47]  J. Massagué,et al.  Transforming growth factor-beta inhibition of epithelial cell proliferation linked to the expression of a 53-kDa membrane receptor. , 1989, The Journal of biological chemistry.

[48]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[49]  G. Fletcher.  Clinical dose-response curves of human malignant epithelial tumours. , 1973, The British journal of radiology.